NU5455 was used to evaluate pharmacological DNA-PKcs inhibition in combination with RT in a cell line panel, including HCC cell lines, by examining the responses of both tumor and normal tissues to treatment. This evidence concerns the gene PRKDC and hepatocellular carcinoma.